|
(5) ¿ÍÀÎÀå ¿ù³Ó
|
|
![](image/board_answer_img_01.gif) |
APEOpYeKhn |
![](image/board_answer_img_04.gif) |
199 |
|
![](image/board_line2.gif) |
I'm unemployed <a href=" http://blog.cilek.com/etiket/ebeveyn/ ">silagra 100 erfahrungen</a> Barres is so confident about his findings that he is already developing a drug to target the complement system in the brain.  In 2011, he co-founded a company, Annexon, which has been working on creating a drug that binds and inhibits the C1q protein.  While their main focus has been on alleviating the effects of Alzheimer’s, Barres said this kind of drug could potentially help those suffering from a full range of neurodegenerative disease. |
![](image/board_line2.gif) |
![](image/board_answer_img_02.gif) |
Jerrod |
![](image/board_answer_img_03.gif) |
2018-11-04 21:25:44 |
|
|
|
|
|
|
|
|